Core Viewpoint - The company is developing a broad-spectrum anti-snake venom antibody using new antibody technology, aiming to create an innovative drug that is universal, has fewer side effects, and is more convenient for use [1] Group 1: Company Development - The company is focused on developing innovative drugs to meet clinical needs in snakebite treatment [1] - The new antibody technology is expected to complement existing anti-snake venom serum, enhancing treatment options [1] - The goal is to improve the company's long-term competitiveness in the field of snakebite diseases [1]

Core Viewpoint - The company, Sairun Biotech, is currently the only domestic player developing antivenom serum for snake bites and is focusing on innovative broad-spectrum antibody technology to maintain its market leadership and address potential competition [1] Group 1: Company Strategy - Sairun Biotech is developing broad-spectrum antivenom antibodies using new antibody technology aimed at creating innovative drugs that are more universal, have fewer side effects, and are easier to administer [1] - The company aims to complement existing antivenom serums with its innovative products to better meet clinical medication needs in various application scenarios [1] Group 2: Market Position - Sairun Biotech acknowledges the presence of four types of venomous snakes in the market but emphasizes its first-mover advantage and technological barriers to sustain its competitive edge [1] - The company is aware of the potential for new entrants in the antivenom serum market and is strategizing to leverage its existing advantages [1]